FDA Speeds Up Pancreatic Cancer Drug Approval Process

The FDA is accelerating the approval process for a pancreatic cancer drug called daraxonrasib. Dr. Janette Nesheiwat, a physician specializing in family and emergency medicine, discussed on ‘Fox Report’ how artificial intelligence might assist in detecting pancreatic cancer earlier.

Daraxonrasib shows early promise as a daily pill aimed at obstructing cancer signals related to the RAS gene. It has completed its initial clinical trial phase, which assessed its safety and effectiveness in humans.

The Dana-Farber Cancer Institute led the trial, involving 168 participants with advanced pancreatic cancer and RAS gene mutations. All patients had previously undergone chemotherapy. Findings were published in The New England Journal of Medicine.

Pancreatic cancer typically presents harmful genetic mutations in more than 90% of cases. Daraxonrasib focuses on blocking several active cancer signals, offering a potential targeted treatment for this type of cancer.

Current drugs targeting RAS mutations often fail to address common pancreatic cancer types. In the trial, a 300-milligram dose yielded a positive response in about 30% of patients, with approximately 90% experiencing either cancer reduction or stabilization.

Reported side effects included rash, mouth inflammation, nausea, and diarrhea. Dr. Brian Wolpin from the Hale Family Center for Pancreatic Cancer Research at Dana-Farber highlighted the potential of this development to revolutionize cancer care. He emphasized that 90% of patients achieved disease control, indicating reduced or stabilized cancer.

If subsequent trials corroborate these findings, daraxonrasib could become significant for nearly all advanced pancreatic cancer patients. Dr. Wolpin added that the trial shows the safety and broad activity of a RAS(ON) multi-selective inhibitor in pancreatic cancer.

The research also indicated that though daraxonrasib results appear better than past chemotherapy trials, the study lacked a randomized control group for direct comparison. As most patients were previously treated, further investigation is necessary to understand its early-stage performance and potential combination with other therapies.

Brian Slomovitz, director of gynecologic oncology at Mount Sinai Medical Center, acclaimed this progress, noting the high prevalence of kRAS activation in pancreatic cancers. He expressed optimism regarding the RASolute 302 study to be presented at an ASCO meeting, which might confirm these promising initial results.

Slomovitz spoke on the potential to double survival time in patients who have undergone prior treatments, marking a notable shift in treatment strategies. He looks forward to reviewing the full dataset to confirm efficacy and safety, expressing enthusiasm for the breakthroughs in treating this challenging disease.